IP Library Patent Application 12839829
Patent Application
App. No. 12/839,829

CANCER TREATMENT USING VIRUSES, FLUOROPYRIMIDINES AND CAMPTOTHECINS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/839,829
Abstract

Mammalian subjects having a neoplasm are treated with a virus, a fluoropyrimidine, for example 5-fluorouracil, and a camptothecin compound. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus.

Claims (15)

1 . A method of treating a mammalian subject having a neoplasm, comprising administering to the subject a virus, a fluoropyrimidine, and a camptothecin compound in one or more cycles in a combined amount effective to treat the subject;

wherein the virus is selected from the group consisting of a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus.

3 . The method of claim 1 , wherein the virus is administered intravenously.

4 . The method of claim 1 wherein the fluoropyrimidine compound is 5-fluorouracil.

5 . The method of claim 4 , further comprising administering to the subject leucovorin.

6 . The method of claim 4 , wherein the 5-fluorouracil is administered by continuous infusion over a period of at least 22 hours per dose.

7 . The method of claim 1 wherein the camptothecin compound is selected from the group consisting of topotecan, 9-aminocamptothecin, exatecan, karenitecin, rubitecan, lurtotecan, and a homocamptothecin.

8 . The method of claim 1 , wherein the camptothecin compound is irinotecan.

9 . The method of claim 1 , wherein the fluoropyrimidine compound is 5-fluorouracil, and the camptothecin compound is irinotecan.

10 . The method of claim 1 , wherein the virus, the fluoropyrimidine compound, and the camptothecin compound are administered in two or more cycles.

11 . The method of claim 1 , wherein the camptothecin compound is administered to the subject from twenty-four hours to one month before administration of the virus.

12 . The method of claim 11 , wherein the camptothecin compound is administered to the subject from twenty-four hours to one week before administration of the virus.

13 . The method of claim 1 , wherein the camptothecin compound is administered to the subject from twenty-four hours to one month after administration of the virus.

14 . The method of claim 13 , wherein the camptothecin compound is administered to the subject from twenty-four hours to one week after administration of the virus.

15 . The method of claim 1 , wherein the neoplasm is a colon carcinoma.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 21, 2021
From: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: WELLSTAT BIOLOGICS CORPORATION
Reel/Frame 055060/0338 →
SECURITY AGREEMENT Recorded Sep 17, 2013
From: WELLSTAT BIOLOGICS CORPORATION
To: PDL BIOPHARMA, INC.
Reel/Frame 031288/0530 →
SECURITY AGREEMENT Recorded Aug 15, 2013
From: WELLSTAT BIOLOGICS CORPORATION
To: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031029/0801 →